Important Perspectives on Innovation and Costs
BIOtech Now Dan Durham This is an exciting time in biomedical innovation. New and highly innovative therapies are coming to market that […]
Category: News
New BIO Report on State of Innovation for Alzheimer’s Disease Therapeutics
BIOtech Now Andrew Segerman Today, BIO released a new report: The State of Innovation in Highly Prevalent Chronic Diseases Volume IV: Alzheimer’s […]
“Health care’s big spending mismatch”
BIOtech Now Andrew Segerman This week, Axios reported on new data that shows “the health care services that rack up the highest […]
New Guide to Help Consumers Navigate Genetic Health Testing
BIOtech Now Jeremy Isenberg In recent years, we have seen a growing array of direct-to-consumer (DTC) genetic testing products rise to the […]
Promising Results Offer Hope in Fight Against Candida auris
BIOtech Now Andrew Segerman While health care conversations on Capitol Hill today are largely focused on how to best lower overall and […]
WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices
BIOtech Now Andrew Segerman This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in Florida to import […]
Greenwood: In Pharma Value Chain, PBMs Manage to Benefit
BIOtech Now Andrew Segerman Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance Committee for calling on […]
BIO Calls Rebate Rule a “Significant Step Forward” for Patients
BIOtech Now Brian Newell The Biotechnology Innovation Organization (BIO) this week lauded an administration proposal that would be a significant step forward […]
A Few Questions as PBMs Have Their Day on Capitol Hill
BIOtech Now Brian Newell Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in the drug cost […]
ICYMI: Dr. Ted Love explains “why drug pricing controls could impede innovation”
BIOtech Now Brian Newell Risky. Costly. Time consuming. Rewarding. Those few words help describe a biopharmaceutical ecosystem where 90% of all clinical […]
Oncologist Warns of IPI’s Potentially Dangerous Implications
BIOtech Now Andrew Segerman Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, Oregon, applauds the […]
Peter Pitts Examines the Role of PBMs and their Deceptive Tactics
BIOtech Now Andrew Segerman A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the Center for Medicine […]
Vaccines Work: the Proof Is in the Data.
BIOtech Now Andrew Segerman At the latest meeting of the Advisory Committee on Immunization Practices (ACIP), more than 80 attendees identified themselves […]
Kentucky Officials Expose PBMs for Gaming the System
BIOtech Now Andrew Segerman While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet for Health and […]
The Empty Promise of “Safe” Drug Importation
BIOtech Now Tom DiLenge For years, BIO has been urging both state and federal policymakers to adopt responsible solutions that would make […]
Two New Infographics Illustrate the Success of the Orphan Drug Act
BIOtech Now Andrew Segerman In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the success of the […]
With an Air of Optimism, #BIOCEO19 Concludes
BIOtech Now Theresa Brady Despite considerable pressure directed squarely at biotech innovators from politicians of every stripe, biotech executives remained focused on […]
#BIOCEO19: Navigating Payers’ Expectations for Value-Based Agreements
BIOtech Now Rufael Seyum Value-based agreements are becoming increasingly important in the biopharmaceutical reimbursement space, particularly as new advanced therapeutic modalities and […]
Health Care in Focus as President Trump Addresses the Nation
BIOtech Now Andrew Segerman In his State of the Union address, President Trump described the need to rein in health care costs […]
Meet Kallyope’s Nancy Thornberry, Fireside Chat Speaker at #BIOCEO19
BIOtech Now Theresa Brady Biotech startups come in all shapes, sizes and approaches but have one thing in common: the drive to […]